The Finnish Medicines Agency Fimea is the national competent authority for regulating pharmaceuticals. As a central administrative agency operating under the Ministry of Social Affairs and Health it promotes the health and safety of the population by regulating medicinal, medical devices, blood and tissue products, biobanks and by developing the pharmaceuticals sector.
Meds75+ database arouses international interest
Fimea has defined further measures for non-transferred clinical trials
Prices of clinical trials to be lowered in special cases
Open data addresses to change at the end of September
Fimea published its sustainability report for 2023, aims for a sustainable future
About Fimea
Fimea’s aim is to improve the pharmaceutical service for the population and the safety, appropriateness and economy of pharmacotherapy. Fimea also enchances and provides the general population and other interested parties with impartial information on medicinal products.
Fimea will work in a close cooperation with relevant parties and stakeholders in the pharmaceutical field. Fimea will also strengthen its collaboration with the European Medicines Agency (EMA) with regard to the regulatory processes of medicinal products in the EU, and will further expand its international cooperation.
Organisation
Fimea's operations are divided into four areas of responsibility, under which the operating entities are grouped: Marketing authorisations, Safety and effectiveness, Supervision and availability and Joint services. In addition, Development and Information Services and Communications Services operate directly under the director general.
Fimea's headquarters are in Kuopio. Fimea also has offices in Helsinki, Turku, Tampere and Oulu.